Endometrial cancer is the fourth most common cancer in women in the United States[@R1] and Europe[@R2], and the most common cancer of the female reproductive system. The familial relative risk is \~2[@R3],[@R4], but highly penetrant germline mutations in mismatch repair genes[@R5], and DNA polymerases[@R6],[@R7] account for only a small proportion of the familial aggregation. Our previous GWAS and subsequent fine-mapping identified the only two reported genome-wide significant endometrial cancer risk loci, tagged by rs11263763 in *HNF1B* intron 1[@R8] and rs727479 in *CYP19A1* intron 4[@R9].

To identify additional endometrial cancer risk loci, we re-analysed data from our previous GWAS (ANECS, SEARCH datasets[@R10]) and conducted a meta-analysis with two further studies ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). The first was an independent GWAS; the National Study of Endometrial Cancer (NSECG), including 925 endometrial cancer cases genotyped using the Illumina 660W array, 1,286 cancer-free controls from the CORGI/SP1 GWAS[@R11],[@R12] and 2,674 controls from the 1958 Birth Cohort[@R13]. The second study comprised 4,330 endometrial cancer cases and 26,849 controls from Europe, the United States and Australia, genotyped using a custom array designed by the Collaborative Oncological Gene-environment Study (COGS) initiative[@R14]--[@R17] ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}, [Supplementary Note](#SD1){ref-type="supplementary-material"}).

We first performed genome-wide imputation using 1000 Genomes Project data, allowing us to assess up to 8.6 million variants with allele frequency ≥1% across the different studies. Per-allele odds ratios and P-values for all SNPs in the GWAS and iCOGS were obtained using a logistic regression model. There was little evidence of systematic overdispersion of the test statistic (λ~GC~=1.002-1.038, [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). A fixed-effects meta-analysis was conducted for all 2.3 million typed and well-imputed SNPs (info score\>0.90) in a total of 6,542 endometrial cancer cases and 36,393 controls. The strongest associations were with SNPs in LD with previously identified endometrial cancer risk SNPs in *HNF1B*[@R8],[@R10],[@R18] and *CYP19A1*[@R9],[@R19] ([Figure 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). For fourteen 1.5Mb regions containing at least one novel SNP with P~meta~\<10^−5^, we performed regional imputation using an additional reference panel that comprised 196 high-coverage whole genome-sequenced UK individuals ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}).

Five novel regions containing at least one endometrial cancer risk SNP with P~meta~\<10^−7^ were identified and the most strongly associated SNP in each region was genotyped in an additional 1,195 NSECG endometrial cancer cases and 751 controls using competitive allele-specific PCR (KASPar, KBiosciences) and the Fluidigm BioMark System ([Supplementary Table 3](#SD4){ref-type="supplementary-material"}). Duplicate samples displayed concordance \>98.5% between different genotyping platforms ([Supplementary Table 4](#SD5){ref-type="supplementary-material"}). All five SNPs were associated with endometrial cancer at genome-wide significance (P\<5×10^−8^, [Table 1](#T1){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}, [Figure 3](#F3){ref-type="fig"}), and these associations remained highly significant when analysis was restricted to cases with endometrioid subtype only. Endometrioid-only analysis did not reveal any additional risk loci. eQTL analysis ([Online Methods](#S2){ref-type="sec"}) in normal uterine tissue[@R20], and endometrial cancer tumor and adjacent normal tissue[@R21] did not yield any SNPs robustly associated with the expression of nearby genes at the endometrial cancer risk loci ([Supplementary Table 5](#SD6){ref-type="supplementary-material"}). However, for each risk locus, bioinformatic analysis including cell-type-specific expression and histone modification data identified correlated SNPs within 500kb in likely enhancers and multiple potential regulatory targets ([Supplementary Table 6](#SD7){ref-type="supplementary-material"}, [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). The most compelling candidates for future functional analysis are described below.

rs13328298 (OR=1.13, 95%CI:1.09--1.18, P=3.73×10^−10^) on 6q22.31 lies in the long non-coding RNA *LOC643623*, 54kb upstream of *HEY2* and 86kb upstream of *NCOA7*. *HEY2* is a helix-loop-helix transcriptional repressor in the Notch pathway, which maintains stem cells, and dysregulation has been associated with different cancers[@R22]. *NCOA7* modulates the activity of the estrogen receptor via direct binding[@R23].

The second locus (rs4733613, OR=0.84, 95%CI:0.80--0.89, P=3.09×10^−9^) is at 8q24.21. Stepwise conditional logistic regression identified another independent signal in this region, rs17232730 (pairwise *r*^*2*^=0.02, P~cond~*=*1.29×10^−5^, [Table 2](#T2){ref-type="table"}). Both endometrial cancer SNPs lie further from *MYC* (784-846kb telomeric) than most of the other cancer SNPs in the region, including those for cancers of the bladder[@R24],[@R25], breast[@R15],[@R26], colorectum[@R12],[@R27], ovary[@R28] and prostate[@R29],[@R30]. rs17232730 is in moderate LD with the ovarian cancer SNP rs10088218 (*r*^*2*^=0.43), with both cancers sharing the same risk allele, but rs4733613 is not in LD (*r*^*2*^*≤*0.02) with any other cancer SNP in the region ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). A role in tumorigenesis is implicated for several miRNAs in the region[@R31]. Of these, miR-1207-5p is reported to repress *TERT*, a locus also implicated in endometrial cancer risk[@R32].

The lead SNP at 15q15 (rs937213; OR=0.90, 95%CI:0.86--0.93, P=1.77×10^−8^) lies within an intron of *EIF2AK4. EIF2AK4* encodes a kinase that phosphorylates EIF2α and downregulates protein synthesis during cellular stress[@R33]. Another nearby gene, *BMF*, encodes an apoptotic regulator moderately to highly expressed in glandular endometrial tissue[@R34].

At 14q42, the lead SNP rs2498796 (OR=0.89, 95%CI:0.85--0.93, P=3.55×10^−8^) lies in intron 3 of oncogene *AKT1*, which is highly expressed in the endometrium[@R34]. Several SNPs in LD with rs2498796 are bioinformatically linked with regulation of *AKT1* and four other nearby genes (*SIVA1, ZBTB42, ADSSL1* and *INF2*; [Supplementary Table 6](#SD7){ref-type="supplementary-material"}, [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). *AKT1* acts in the PI3K/AKT/MTOR intracellular signaling pathway, which affects cell survival and proliferation[@R35] and is activated in endometrial tumors[@R36], especially aggressive disease[@R37]--[@R39]. *SIVA1* encodes an apoptosis regulatory protein that inhibits p53 activity[@R40],[@R41] and enhances epithelial--mesenchymal transition to promote motility and invasiveness of epithelial cells[@R42]. *INF2* expression is reported to act as a promigratory signal in gastric cancer cells treated with mycophenolic acid[@R43].

The final novel endometrial cancer SNP was rs11841589 (OR=1.15, 95%CI:1.11--1.21, P=4.83×10^−11^) on chromosome 13q22.1, 163kb and 445kb downstream from Kruppel-like factors *KLF5* and *KLF12*, respectively. KLF5 is a transcription factor associated with cell cycle regulation, and it plays a role in uterine development, homoeostasis and tumorigenesis[@R44]--[@R47]. Elevated *KLF5* levels are strongly correlated with activating *KRAS* mutations [@R48] and KLF5 is targeted for degradation by the tumor suppressor FBXW7. Both *FBXW7* and *KRAS* are commonly mutated in endometrial cancer [@R49]. rs11841589 was one of a group of five highly correlated SNPs (*r*^*2*^*≥* 0.98) surpassing genome-wide significance in a 3kb LD block bounded by rs9600103 (P=8.70×10^−11^) and rs11841589 ([Figure 4a](#F4){ref-type="fig"}). There was no residual association signal at this locus (P~cond~ \>0.05) after conditioning for rs11841589. Bioinformatic analysis suggested that the causal variant at the intergenic 13q22.1 locus may affect a regulatory element that modifies *KLF5* expression ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}); rs9600103 overlaps a vertebrate conservation peak, and a DNaseI hypersensitivity site (DHS) in estrogen and tamoxifen-treated ENCODE[@R50] Ishikawa cells ([Figure 4a](#F4){ref-type="fig"}). In addition, in a Hi-C chromatin capture experiment in Hela S3 cells[@R51], a chromatin interaction loop was observed between a segment containing the *KLF5* promoter and the rs11841589/rs9600103 locus (P=0.004, [Supplementary Figure 4](#SD1){ref-type="supplementary-material"}).

We further investigated the epigenetic landscape of a 16kb region around rs11841589 and rs9600103 that contained the SNPs most strongly associated with endometrial cancer, by analysis of three endometrial cancer cell lines: Ishikawa (homozygous for the rs9600103-A and rs11841589-G high-risk alleles and provides a comparison with the ENCODE data); ARK-2 (homozygous for the low-risk T alleles at both SNPs); and AN3CA (a non-*KLF5* expressing line that is homozygous for the high-risk alleles) ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}). We conducted formaldehyde-assisted identification of regulatory elements (FAIRE, to identify regions of open chromatin), and chromatin immunoprecipitation (ChIP) using antibodies against H3K4Me2 (marker of transcription factor binding[@R52]) and panH4Ac (marker of active chromatin). Although the anti-H4Ac ChIP did not display a consistent signal in the region, peaks in signals from FAIRE and anti-H3K4Me2 ChIP were specifically present in the *KLF5-*expressing lines and were co-located with the conservation peak and DHS from the ENCODE data at rs9600103, providing strong evidence for open chromatin and transcription factor binding at this site ([Figure 4a](#F4){ref-type="fig"}). We then conducted chromatin conformation capture experiments for the *KLF5*-expressing Ishikawa endometrial cancer cells ([Supplementary Figure 5](#SD1){ref-type="supplementary-material"}) and found a significant interaction between the *Nco*I restriction fragment containing the rs11841589/rs9600103 risk loci SNPs and the promoter region of *KLF5* ([Figure 4b](#F4){ref-type="fig"}).

The regulatory nature of the region around rs11841589/rs9600103 was investigated using allele-specific luciferase reporter assays in Ishikawa cells ([Figure 4c)](#F4){ref-type="fig"}. Paired t-tests were used to compare the relationships between fragments containing the rs11841589 and rs9600103 alleles, and the pGL3-Promoter reporter vector (no insert) control ([Supplementary Table 7](#SD8){ref-type="supplementary-material"}). Fragments containing the rs9600103-T, rs11841589-T and rs11841589-G alleles had activity significantly lower than that of the pGL3-Promoter control (P≤0.014). In contrast, the construct containing the rs9600103-A risk allele had luciferase expression similar to the pGL3-Promoter control (P=0.23) and significantly higher than that of the corresponding rs9600103-T protective allele (P=0.02). These results suggest that the endometrial cancer risk tagged by rs11841589 is at least partly due to a regulatory element containing rs9600103, which interacts with the *KLF5* promoter region, with the risk rs9600103-A allele likely associated with increased gene expression.

In summary, this meta-analysis identified five novel endometrial cancer risk loci at genome-wide significance, bringing the total number of common endometrial cancer risk loci identified by GWAS to seven ([Figure 1](#F1){ref-type="fig"}). Together with other risk SNPs reaching study-wide significance[@R32],[@R53],[@R54], these explain \~5.1% of the endometrial cancer familial relative risk. Novel endometrial cancer risk SNPs lie in likely enhancers predicted to regulate genes or miRNAs with known or suspected roles in tumorigenesis, and we specifically showed that a functional SNP at 13q22.1 may sit within a transcriptional repressor of *KLF5*. Our findings further clarify the genetic etiology of endometrial cancer, provide regions for functional follow-up, and add key information for future risk stratification models.

URLs {#S1}
====

rmeta, <http://cran.r-project.org/web/packages/rmeta/>

The Cancer Genome Atlas (TCGA) <http://www.cancergenome.nih.gov/>

Online Methods {#S2}
==============

Cases and controls were matched as summarized in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Each sample set is described in the [Supplementary Note](#SD1){ref-type="supplementary-material"}. [Supplementary Figure 1](#SD1){ref-type="supplementary-material"} illustrates the overall study design.

Additional EC GWAS {#S3}
------------------

The National Study of Endometrial Cancer Genetics (NSECG) consisted of 925 histologically confirmed endometrial cancer cases from the UK; 86% with endometrioid-only histology. Genotyping was done using Illumina 660W Quad arrays.

These cases were matched with 1,286 cancer-free controls from the UK1/CORGI[@R12] and SP1[@R11] colorectal studies genotypedusing Illumina Hap550, Hap300 and Hap240S arrays, and. 1958 Birth Cohort[@R55] controls from the Wellcome Trust Case Control Consortium (WTCCC2)[@R13] genotyped using Illumina Infinium 1.2M arrays.

Original endometrial cancer GWAS {#S4}
--------------------------------

As described previously, cases with endometrioid histology were selected from two population studies; the UK Studies of Epidemiology and Risk factors in Cancer Heredity (SEARCH, n=681) and the Australian National Endometrial Cancer Study (ANECS, n=606), and genotypes generated using Illumina Infinium 610K arrays [@R10]. Compared with our previous study [@R10], this meta-analysis analysed ANECS and SEARCH as two groups and included additional controls[@R8],[@R56]. SEARCH cases were compared with 2,501 controls from the National Blood Service (NBS) part of the WTCCC2 controls [@R13]. ANECS cases were compared to controls recruited as part of the Hunter Community Study[@R56] or Brisbane Adolescent Twin Study[@R57], genotyped using Illumina Infinium 610K arrays.

Phase 1 iCOGS genotyping {#S5}
------------------------

For the iCOGS genotyping stage, 4,330 women with a confirmed diagnosis of endometrial cancer and European ancestry were recruited via 11 studies in Western Europe, North America and Australia, collectively called the Endometrial Cancer Association Consortium (ECAC).

Healthy female controls with European ancestry and known age at sampling were selected from controls genotyped by the Breast Cancer Association Consortium (BCAC)[@R15] or Ovarian Cancer Association Consortium (OCAC)[@R16] iCOGS projects. Eight case-control groups were matched based on geographical location, and principal components analysis (PCA) conducted; individuals who clustered outside the main centroid in pairwise plots of the first four PCs were excluded ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}).

Cases and controls were genotyped on a custom Illuminia Infinium iSelect array with 211,155 SNPs, designed by the Collaborative Oncological Gene-environment Study (iCOGS), a collaborative project involving four consortia. SNPs were included on this array based on promising regions of interest in previous breast, ovarian and prostate[@R14] studies, and also the 1,483 top SNPs from our previous EC GWAS[@R10] analysis. Cases and MoMaTEC controls were genotyped by Genome Quebec Innovation Center. BCAC and OCAC control samples were genotyped at four centres. Raw intensity data files for all consortia were sent to the COGS data co-ordination centre at the University of Cambridge for centralized genotype calling and quality control (QC), so that all case and control genotypes were called using the same procedure.

SNP genotyping arrays quality control {#S6}
-------------------------------------

Genotype calling was done using Illumina's proprietary Gencall algorithm and Illumnus[@R58]. Duplicate samples displayed \>99% concordance. Standard QC measures applied to genotyping arrays are described in our original GWAS [@R10] and include: genotypic call rate \<0.95; deviation from Hardy-Weinberg Equilibrium (HWE) at P\<10^-6^; visual inspection of cluster plots for most significant SNPs. For iCOGS, all endometrial cancer cases and MoMaTEC controls were genotyped by Genome Quebec Innovation Center. BCAC and OCAC control samples were genotyped at four centres. Raw intensity data files for all consortia were sent to the COGS data co-ordination centre at the University of Cambridge for centralized genotype calling and QC, so that all case and control genotypes were called using the same procedure. Duplicate samples for QC showed a concordance of \>99%. Samples were excluded based on the following measures: missingness \>5%, heterozygosity rates ((N-O)/N) \> 5 S.D from the mean, X chromosome heterozygosity rate (PLINK F-score) \>0.2, and pairwise identity by descent (IBD) \>0.1875 (cut-off for second-degree relatives). PCA was conducted using Eigenstrat[@R59] software. Analysis was conducted using PLINK[@R60], and R packages GenABEL and SNPMatrix[@R61],[@R62].

Phase 2 NSECG genotyping {#S7}
------------------------

A second genotyping phase consisted of assaying five SNPs with P\<10^-7^ and IMPUTE info scores of \>0.94 from the NSECG/ANECS/SEARCH/iCOGS meta-analysis; samples were NSECG cases and controls not previously been used in the NSECG GWAS or NSECG iCOGS. Genotyping was conducted using competitive allele-specific PCR (KASPar, KBiosciences) and the Fluidigm BioMark^TM^ HD System, using standard protocols. The genotyping call rate was \>0.98 and there was a \>0.985 concordance between different genotyping platforms ([Supplementary Table 4](#SD5){ref-type="supplementary-material"}). There was no significant deviation from HWE (P\>0.05). Genotyping primers are listed in [Supplementary Table 8](#SD9){ref-type="supplementary-material"}.

Genome-wide and regional imputation {#S8}
-----------------------------------

Genome-wide imputation for all SNP array generated data was conducted using IMPUTE v2[@R63] and 1000 Genomes project (2012 release) as reference panel. For the first-pass genome-wide analysis we pre-phased chromosomes using SHAPEIT[@R64] to improve the computational speed. Imputation was carried out separately for the each of the three GWAS studies (for each GWAS study the cases and controls were imputed together as a single dataset, using only SNPs which passed QC in both cases and controls) and for the iCOGS study (all studies within iCOGS were imputed together). SNPs with MAF\<0.1% were removed from all studies prior to imputation. Genome-wide imputation produced 9,594,066 SNPs with MAF≥1% and info≥0.4 in at least one of the three GWAS and eight iCOGS groups. Of these, 8,308,423 SNPs met these criteria in all studies. The iCOGS genotyping array (\~200,000 SNPs) is aimed at capturing previously prioritised cancer SNPs and not genome-wide coverage, but nonetheless 8,631,871 SNPs met MAF≥1% and info≥0.4 criteria, of which 5,437,135 had info≥0.7 and 2,333,040 had info≥0.9.

Regional imputation of regions of interest (1.5Mb region around SNPs with meta-analysis P\<10^-5^) used both 1000 Genomes 2012 release and 196 high-coverage, whole genome-sequenced UK individuals as reference panels as a means to improve imputation accuracy[@R65]. All SNPs reported in this study had an info score ≥0.9 in all datasets.

Association testing {#S9}
-------------------

Association testing was done using SNPTEST v2[@R66] employing frequentist tests with a logistic regression model for each of the 11 groups as matched in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. There was little evidence of systematic over-dispersion of the test statistic from the quantile-quantile plots ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}) and the genomic inflation λ~GC~, calculated using all genotyped SNPs passing QC for the three GWAS. For iCOGS, 105,000 SNPs after LD-pruning (*r*^*2*^\<0.2) and \>500kb from the 1,483 EC prioritized SNPs on the iCOGS were used. λ~GC~ was between 1.002 and 1.038 for each study. Conditional logistic regression analysis was conducted for each locus of genome-wide significance using SNPTEST to look for the presence of multiple independent association signals. This was done in a stepwise manner, first conditioning for the most significant SNP and subsequently for any SNPs that remained significant at P~cond~\<10^-4^. Regional association plots ([Figure 1](#F1){ref-type="fig"}, [Supplementary Figure 6](#SD1){ref-type="supplementary-material"}) were created using LocusZoom[@R67].

Meta-analysis {#S10}
-------------

Inverse variance, fixed effects meta-analysis of the 11 groups (three GWAS, eight iCOGS groups) was conducted using GWAMA[@R68]. The per allele effect size of each SNP in a particular study is represented by β (the log-odds ratio) and its standard error. Inter-study differences are represented by the I^2^ heterogeneity score[@R69],[@R70]. Forest plots of the genome-wide significant loci ([Figure 2](#F2){ref-type="fig"}) representing risk effects across different studies were made using rmeta. A random-effects meta-analysis was also performed for SNPs with I^2^\<0.3. The results of the second replication phase (NSECG replication) were meta-analyzed in a 12-way meta-analysis for the top 5 SNPs yielding a total of 7,737 EC cases and 37,144 controls. 6,635 (86%) of the EC cases had endometrioid-only histology and association testing and meta-analysis were also conducted with just these samples.

Bioinformatic analysis and functional annotation of genome-wide significant risk loci {#S11}
-------------------------------------------------------------------------------------

The five novel genome-wide significant loci and SNPs in LD (r^2^\>0.7 in European 1000 Genomes) were annotated using HaploregV2[@R71], RegulomeDB[@R72] and data from ENCODE[@R50] in [Supplementary Table 6](#SD7){ref-type="supplementary-material"}. This includes information such as promoter and enhancer histone marks, DHS, bound proteins, altered motifs, GENCODE and dbSNP annotations, RegulomeDB score and PhastCons conservation scores.

Bioinformatic analysis in [Supplementary Figure 3](#SD1){ref-type="supplementary-material"} used datasets described by Hnisz *et al*. [@R73] and Corradin *et al*. [@R74] to identify likely enhancers in a cell-specific context for the risk loci. Enhancer-gene interactions are predicted by identifying 'super-enhancers' (regions containing neighbouring H3K27Ac modifications) from 86 cell and tissue types and then the expressed transcript with transcription start site closest to the centre of the super-enhancer was assigned as the target gene. PresTIGE pairs cell-type specific H3K4Me1 and gene expression data from 13 cell types to identify likely enhancer-gene interactions.

Endometrial-tissue expression quantitative trait loci (eQTL) analysis for associated SNPs using GTEx and TCGA data {#S12}
------------------------------------------------------------------------------------------------------------------

Publicly available data generated by the Genotype-Tissue Expression Project (GTEx)[@R20] and The Cancer Genome Atlas (TCGA) were accessed to examine tissue-specific eQTLs. For GTEx, expression and genotype data were generated from 70 normal uteri from post-mortem biopsies, using an Affymetrix Expression array and Illumina Omni 5M SNP array. GTEx provided processed results, evaluating association between genotype and expression data. The expression levels are represented as a rank normalized score. TCGA genotype and copy number variation (CNV) data were derived from Affymetrix 6.0 SNP arrays. Expression data were from RNAseq arrays (Illumina HiSeq and Illumina GA) for 458 endometrial cancer tissues and 30 adjacent normal endometrial tissues. Association analyses for TCGA datasets were performed as follows. Genes within 500kb flanking our SNPs of interest were selected for analysis. Since there may be significant variation in tumour tissue copy number, somatic CNVs were taken into account by regressing gene expression to average copy number spanning the gene. Residual unexplained variance in gene expression was then regressed on the genotype of the lead SNP at each locus, using genotyped or imputed data. Statistical comparisons were subject to Bonferroni correction for number of tests (number of sample sets, and number of genes assessed).

DNA and RNA extraction from cell lines {#S13}
--------------------------------------

Cell lines were from the laboratory of Dr David Church, acquired as gifts from Brittia Weigelt (currently at Memorial Sloan Kettering, USA), and Konstantin Dedes (University of Zurich, Austria), were routinely tested for mycoplasma contamination. Somatic mutation data generated previously matches that reported in publicly available resources and the literature, where available. Cells were snap frozen with dry ice after centrifugation, and DNA and RNA extracted using DNeasy and RNeasy minikits (Qiagen). Nucleic acids were quantified using Nanodrop 2000 (ThermoScientific) spectrophotometry.

Quantification of *KLF5* expression in endometrial cancer cell lines {#S14}
--------------------------------------------------------------------

Extracted RNA was treated with DNase 1, and complimentary DNA (cDNA) was reverse transcribed from RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). TaqMan Gene Expression Assays were used for *KLF5* and *GAPDH* (details available from authors). The absolute expression of *KLF5* was quantified using qRT-PCR using the ABI 7900HT cycler (Applied Biosystems), and the critical threshold was manually set at 0.2. Relative expression was calculated using the ΔΔCT method described by Livak and Schmittgen[@R75], with *GAPDH* as an endogenous control.

Formaldehyde-assisted identification of regulatory elements (FAIRE) {#S15}
-------------------------------------------------------------------

Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) was conducted using the method adapted from Giresi et al[@R76]. Briefly, cross-linking was done on a rocker at room temperature. 1% formaldehyde was added to \~10[@R8] cells for 5 minutes, and 115mM glycine added to inhibit cross-linking. For each cell line, a non-crosslinked control was prepared in parallel for all remaining steps. After two rinses with 4°C phosphate buffered saline solution (PBS), cells were suspended in successive buffers: Lysis buffer I (50mM HEPES-KOH, 140mM NaCl, 1mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% tritonX-100); lysis buffer II (10mM tris-HCl, 200mM NaCl, 1mM EDTA, 0.5mM EGTA); lysis buffer III (10mM tris-HCl, 2100mM NaCl, 1mM EDTA, 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine). Cells were incubated on a rocker at 4°C for 10 minutes in each lysis buffer, thenspun down at 1300 g for 5 minutes, and the supernatant removed. The cells were then sonicated using the Bioruptor in seven to fifteen 30-second cycles to generate fragments 100-1000 bp in size, and gel electrophoresis in 1% agarose used to confirm DNA fragment sizes. The DNA was extracted with a standard phenol/chloroform method and ethanol-precipitated. 50ng of DNA from paired crosslinked and non-crosslinked cells was analyzed in duplicate by SYBR-green quantitative PCR (qPCR) using primers at \~1kb intervals in the 13q22.1 region downstream of *KLF5* ([Supplementary Table 8](#SD9){ref-type="supplementary-material"}). The ΔΔCt method[@R31] was used to normalize results to the input DNA from non-crosslinked cells and then expressed relative to the Rhodopsin promoter as negative control. For each experiment there were two replicates for the crosslinked cells and non-crosslinked controls, each performed on two occasions.

Cross-linked Chromatin immunoprecipitation (ChIP) {#S16}
-------------------------------------------------

About 10^8^ cells were cross-linked using 1% formaldehyde for 10 minutes. Glycine was used to stop the cross-linking, cells were then rinsed twice in PBS, and cell scrapers used to detach cells adhered to the Petri dish surface. Cells were then resuspended in lysis buffer (1% sodium dodecyl sulfate (SDS), 10mM EDTA (Ambion), 50mM Tris-HCl (Ambion)) incubated for 10 minutes, and then sonicated using the Bioruptor (Diagenode) in 7 to 15 30-second cycles to generate fragments 1000-1500 bp in size. Gel electrophoresis in 1% agarose confirmed the size of the DNA fragments. The fragmented DNA was then diluted ten times to the immuno-precipitation dilution buffer (1% tritonX-100, 2nM EDTA, 20mM Tris-HCl, 150mM sodium chloride and each cell line was separated into four tubes: input chromatin, no-antibody-control and one tube for each antibody. 5ul of anti-dimethyl-histone H3 Lys4 (Millipore 07-030) and anti-acetyl-histone H4 (Millipore 06-866) were added to the antibody tubes and, along with the no-antibody-control, incubated overnight at 4°C for immunoprecipitation. The input chromatin was kept refrigerated at 4°C until the reverse cross-linking of day 2. Phenylmethylsulfonyl fluoride and protease inhibitor was added to the lysis buffer and IP dilution buffer to deactivate proteases, while sodium butyrate was added to these solutions to inhibit histone deacetylases. 5ul of protein A Dynabeads was added to each tube and incubated for 4 hours. A series of washes were done using Tris/Sucrose/EDTA (TSE) I (1% tritonX-100, 2mM EDTA, 20mM Tris-HCl, 150mM NaCl, 0.1% SDS), TSE II (1% tritonX-100, 2mM EDTA, 20mM Tris-HCl, 500mM NaCl, 0.1% SDS), Buffer III (0.25M lithium chloride, 1mM EDTA, 10mM Tris-HCl, 1% tergitol-type NP-40, 1% sodium deoxycholate) and tris-EDTA (1X). 300ul of extraction solution (1% SDS 0.1M sodium bicarbonate) was added and Dynabeads were removed after a 30 minute incubation. Then 0.7 M NaCl was added and reverse cross-linking occurred overnight at 65°C. DNA was purified using the QIAquick PCR purification kit (Qiagen). 1ul of DNA was analyzed in duplicate or triplicate by SYBR green qPCR as above and the ΔΔCt method was used to identify areas with enrichment. For each experiment there were two replicates for each antibody along with the input and no-antibody control, each performed on two occasions. Primers used are listed in [Supplementary Table 8](#SD9){ref-type="supplementary-material"}.

Chromatin conformation capture (3C) {#S17}
-----------------------------------

Experiments were performed as described in Ghoussaini *et al*.[@R77] , using the *KLF5*-expressing Ishikawa endometrial cancer cell line from ATCC. The cell line was authenticated using a short tandem repeat (STR) profiling, and routinely tested for mycoplasma contamination (QIMR Berghofer in-house Support Services). Briefly, Ishikawa cell lines were crosslinked with 1% formaldehyde for 10 mins, quenched with 125mM glycine, washed with PBS and collected by scraping. Cells were lysed for 30 min on ice in 10mM Tris-HCl, pH 7.5, 10mM NaCl, 0.2% Igepal with protease inhibitors and homogenized in a Dounce homogenizer. Nuclei were pelleted and resuspended in 1ml 1.2X restriction buffer (NEB 3.1) with 0.3% SDS for 1h at 37°C. 2% Triton X-100 was added then 1000U NcoI was added 3 times over 24h at 37°C with shaking. The enzyme was inactivated, and digested DNA diluted 8X before ligation with 4000U of T4 DNA ligase overnight at 16°C. Crosslinks were reversed by proteinase K digestion at 65°C overnight, and the DNA purified by phenol--chloroform extraction and ethanol precipitation. The final DNA pellet was dissolved in 10mM Tris (pH 7.5) and purified through Amicon Ultra 0.5 ml columns (Millipore). 3C interactions were quantified by SYTO9 qPCR (performed on a RotorGene 6000) using primers designed to amplify across ligated NcoI restriction fragments with one constant primer within the risk fragment (including rs11841589 and rs9600103) and a series of test primers within *Nco*I fragments spanning 76 kb of the *KLF5* promoter region. BAC clones (RP11-81D9, RP11-179I20) covering the region were digested with *Nco*I, ligated with T4 ligase and used determine PCR efficiency. 3C analyses were performed on three independent 3C libraries, with each data point in duplicate. Data were normalized to the signal from the BAC clone library and from a non-interacting chromosomal region using the ΔΔCt method with incorporated individual primer pair efficiencies.

Luciferase reporter assays {#S18}
--------------------------

For luciferase reporter assays, the regions chr:13 73,810,509-73,813,452 around rs9600103 and chr13:73,813,268-73,816,290 around rs11841589 were cloned into the pGL3-Promoter vector (Promega) to test for regulatory effects in Ishikawa cells. Ishikawa cells were selected because they express *KLF5*, showed evidence of a DHS, FAIRE and H3K4Me2 enrichment at rs9600103 and were readily transfectable. Site-directed mutagenesis was used so both the high- and low-risk alleles of rs9600103 and rs11841589 were tested. After sequencing to verify the correct insert sequences, cells were transiently co-transfected using lipofectamine with the appropriate pGL3-Promoter constructs, and the Renilla luciferase pGL4.75 vector (Promega) as control for transfection efficiency. After 48 hours, luciferase activity was measured (Dual-Glo Luciferase Assay System, Promega), and after subtracting background from lipofectamine-only controls, firefly luciferase activity from the putative enhancer regions was normalized to the Renilla luciferase values for each sample. Levels of firefly luciferase activity were compared with a control plasmid consisting of an empty pGL3, and also a noncoding 2.2-kb stretch of plasmid sequence from the pENTR1A plasmid (Invitrogen) cloned into the pGL3-Promoter vector previously used as a length of DNA with no regulatory activity[@R78]. Luciferase activity experiments had three or four replicates, each performed on three occasions (total of 11 assays). Primers used are listed in [Supplementary Table 8](#SD9){ref-type="supplementary-material"}.

ANOVA found significant differences in luciferase levels (P\<0.0001, F:11.6) but no significant differences between replicates conducted on different days (P=0.91, F:0.09). There were no significant differences between the pENTR1A control and the empty pGL3-Promoter vector (P=0.085); pGL3-Promoter vector was used as control. We conducted paired t-tests for all comparisons using the average of biological repeats, between the pGL3 no insert, rs9600103-A, rs9600103-T, rs11841589-G and rs11841589-T fragments ([Supplementary Table 7](#SD8){ref-type="supplementary-material"}, results unadjusted for multiple comparisons).
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![Endometrial cancer meta-analysis Manhattan plot\
Manhattan plot of −log~10~-transformed P-values from meta-analysis of 22 autosomes. There are seven loci surpassing genome-wide significance including two known loci: 15q21 (*CYP19A1*) and 17q12 (*HNF1B*) and five novel loci: 6q22 (*NCOA7, HEY2*), 8q24 (*MYC*), 13q22 (*KLF5*), 14q32 (*AKT1, SIVA1*), 15q15 (*EIF2AK4, BMF*).](emss-68408-f001){#F1}

![Forest plots of novel endometrial cancer risk loci\
The odds ratio and 95% confidence intervals of each study of the meta-analysis are listed and shown in the adjacent plot. The I^2^ heterogeneity scores (all \<0.4) suggest that there is no marked difference in effects between studies. The SNPs represented are: a) rs11841589 (13q22), b) rs13328298 (6q22), c) rs4733613 (8q24), d) rs17232730 (8q24, pairwise *r^2^* 0.02 with rs4733613), e) rs937213 (15q15) and f) rs2498796 (14q32).](emss-68408-f002){#F2}

![Regional association plots for the five novel loci associated with endometrial cancer.\
The −log~10~ P-values from the meta-analysis and regional imputation for three GWAS and eight iCOGS groups are shown for SNPs at: a) 13q22.1, b) 6q22, c) & d) 8q24, e) 15q15 and f) 14q32.33. The SNP with the lowest P-value at each locus is labeled and marked as a purple diamond, and the dot color represents the LD with the top SNP. The blue line shows recombination rates in cM/Mb. All plotted SNPs are either genotyped or have an IMPUTE info score of more than 0.9 in all datasets. Although genome-wide significant results for the 14q32.33 locus rely on imputed data, it should be noted that there is strong support from nearby genotyped markers. [Supplementary Figure 6](#SD1){ref-type="supplementary-material"} displays similar regional association plots with a larger number of SNPs using a less stringent info score cut-off.](emss-68408-f003){#F3}

![The 13q22.1 endometrial cancer susceptibility locus\
a) Diagram showing the 16kb region around rs11841589, rs9600103 and correlated SNPs rs7981863, rs7988505 and rs7989799 (black marks), DNaseI hypersensitivity site (DHS) density signal in estrogen- and tamoxifen-treated ENCODE Ishikawa cells ([Supplementary Note](#SM){ref-type="supplementary-material"}), and 100 vertebrates conservation. Vertical dotted line represents the position of rs9600103. FAIRE and ChIP assays for H3K4Me2 and H4Ac in endometrial cancer cell lines ARK-2 (rs9600103-TT), Ishikawa (rs9600103-AA) and AN3CA (rs9600103-AA) show evidence for enrichment of histone modifications.\
b) 3C experiment for KLF5-expressing Ishikawa cells. Relative interaction frequencies between an *Nco*I restriction fragment containing risk SNPs rs9600103 and rs11841589 (bait fragment) and *Nco*I fragments across the *KLF5* promoter region, plotted against fragment position on chromosome 13. *Nco*I restriction sites are displayed below the schematic of *KLF5* transcripts. H3K4Me3 binding, indicative of promoters, from multiple ENCODE cell lines are also shown.. The graph represents three biological replicates. Error bars represent standard deviation. A significant interaction was seen with the fragment containing a *KLF5* transcriptional start site (fragment shaded in grey).\
c) Luciferase reporter assays to analyze the activity of 3kb fragments containing either rs9600103 or rs11841589 using the pGL3-Promoter vector in Ishikawa cells. Green arrows represent the low-risk alleles, and red arrows the high-risk alleles. Error bars represent the standard error of the mean (n=3). Luciferase activity for the rs9600103-A risk allele was more than double that of the rs9600103-T protective allele (P=0.018). There was no significant difference in luciferase activity between the rs11841589 alleles ([Supplementary Table 7](#SM){ref-type="supplementary-material"}).](emss-68408-f004){#F4}

###### Risk loci associated with endometrial cancer at *P*\< 5×10^−8^ in the meta-analysis.

                                      All histologies   Endometrioid histology                                                                                                             
  ----------------------------------- ----------------- ------------------------ --------------- --- --- ------ ------------------ -------------- ------ ------------------ -------------- ------
  **Novel GWAS loci**                                                                                                                                                                      
  13q22.1                             rs11841589          73,814,891             *KLF5, KLF12*   G   T   0.74   1.15 (1.11-1.21)   4.83×10^−11^   0.19   1.16 (1.10-1.21)   6.01×10^−10^   0.00
  6q22.31                             rs13328298        126,016,580              *HEY2, NCOA7*   G   A   0.58   1.13 (1.09-1.18)   3.73×10^−10^   0.00   1.15 (1.11-1.20)   1.02×10^−11^   0.00
  8q24.21                             rs4733613         129,599,278              *MYC*           G   C   0.87   0.84 (0.80-0.89)   3.09×10^−9^    0.00   0.84 (0.79-0.89)   7.70×10^−9^    0.09
  15q15.1                             rs937213            40,322,124             *EIF2AK, BMF*   T   C   0.58   0.90 (0.86-0.93)   1.77×10^−8^    0.36   0.90 (0.86-0.94)   2.22×10^−7^    0.30
  14q32.33                            rs2498796         105,243,220              *AKT1, SIVA1*   G   A   0.70   0.89 (0.85-0.93)   3.55×10^−8^    0.00   0.88 (0.85-0.92)   4.22×10^−8^    0.00
  **Previously reported GWAS loci**                                                                                                                                                        
  17q12                               rs11263763        36,103,565               *HNF1B*         A   G   0.54   1.20 (1.15-1.25)   2.78×10^−19^   0.37   1.20 (1.15-1.25)   6.51×10^−17^   0.52
  15q21                               rs2414098         51,537,806               *CYP19A1*       C   T   0.62   1.17 (1.13-1.23)   4.51×10^−13^   0.00   1.18 (1.13-1.23)   2.48×10^−13^   0.00

Positions in build 37; EA, Effect allele; OA, Other allele; EAF, effect allele frequency; I^2^, heterogeneity I^2^ statistic[@R55]. For all novel loci, the lead SNP was either directly genotyped or imputed with an information score of more than 0.9. *HNF1B* and *CYP19A1* have been previously reported by Painter *et al*.[@R8] and Thompson *et al*[@R9].

###### Conditional analysis of 8q24 locus showing two independent association signals.

  SNP                                          Position      EA   OA   EAF    Pairwise *r^2^* with   All histology meta-analysis   Conditioning on rs4733613   Conditioning on rs17232730                                                         
  -------------------------------------------- ------------- ---- ---- ------ ---------------------- ----------------------------- --------------------------- ---------------------------- ------------------ --------------- ------------------ ---------------
  rs4733613                                    129,599,278   G    C    0.87   \-                     0.02                          0.84 (0.79-0.89)            5.64 × 10^−9^                \-                 \-              0.86 (0.81-0.91)   2.32 × 10^−7^
  rs17232730                                   129,537,746   G    C    0.88   0.02                   \-                            1.17 (1.10-1.24)            4.46 × 10^−7^                1.14 (1.08-1.22)   1.29 × 10^−5^   \-                 \-
  rs10088218[\*](#TFN3){ref-type="table-fn"}   129,543,949   G    A    0.87   0.02                   0.43                          1.14 (1.07-1.20)            1.65 × 10^−5^                1.12 (1.05-1.18)   2.92 × 10^−4^   1.01 (0.91-1.12)   0.818

Positions in build 37; EA, Effect allele; OA, Other allele; EAF, effect allele frequency.

rs10088218 is associated with ovarian cancer (all subtypes), with the association being more significant for cancers of serous histology. rs10088218-G is the risk allele for both endometrial cancer and ovarian cancer.
